IMDX

3.275

8.80% 0.265

Handel nachbörslich: 3.23 -0.045 -1.37%

Insight Molecular Diagnostics Inc (IMDX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$3.01

Offen:

$3.11

24-Stunden-Volumen:

33,706

Relative Volume:

1.14

Marktkapitalisierung:

$93.73M

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

EPS:

Netto-Cashflow:

1W Leistung:

-1.06%

1M Leistung:

+26.45%

6M Leistung:

+0.00%

1J Leistung:

+0.00%

1-Tages-Spanne:

$3.03

$3.29

1-Wochen-Bereich:

$3.01

$3.57

52-Wochen-Spanne:

$2.33

$3.598

Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile

Firmenname

Insight Molecular Diagnostics Inc

Sektor

Healthcare (1150)

Branche

Diagnostics & Research (53)

Telefon

949-409-7600

Adresse

2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

IMDX's Discussions on Twitter

Vergleichen Sie IMDX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IMDX Insight Molecular Diagnostics Inc	3.275	86.15M	0	0	0	0.00
TMO Thermo Fisher Scientific Inc	468.00	177.38B	43.21B	6.58B	6.17B	17.29
DHR Danaher Corp	185.91	135.85B	24.01B	3.41B	4.86B	4.70
IDXX Idexx Laboratories Inc	627.17	51.87B	4.04B	985.66M	774.34M	12.01
A Agilent Technologies Inc	124.38	35.70B	6.79B	1.22B	1.09B	4.26
IQV Iqvia Holdings Inc	181.24	31.70B	15.70B	1.24B	2.01B	6.91

Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-28	Eingeleitet	Lake Street	Buy
2022-05-24	Herabstufung	Stephens	Overweight → Equal-Weight
2022-03-14	Herabstufung	KeyBanc Capital Markets	Overweight → Sector Weight
2022-01-07	Eingeleitet	Stephens	Overweight
2022-01-06	Fortgesetzt	Piper Sandler	Overweight
2021-03-17	Fortgesetzt	Needham	Buy
2021-01-07	Hochstufung	The Benchmark Company	Speculative Buy → Buy
2020-12-16	Hochstufung	Piper Sandler	Neutral → Overweight
2020-11-30	Eingeleitet	BTIG Research	Buy
2020-11-10	Eingeleitet	KeyBanc Capital Markets	Overweight
2020-07-30	Bestätigt	The Benchmark Company	Speculative Buy
2020-07-01	Herabstufung	Piper Sandler	Overweight → Neutral
2020-06-30	Herabstufung	Chardan Capital Markets	Buy → Neutral
2020-06-02	Eingeleitet	Needham	Buy
2019-02-13	Eingeleitet	Piper Jaffray	Overweight
2019-01-29	Hochstufung	Janney	Neutral → Buy
2018-12-19	Fortgesetzt	Lake Street	Buy

Alle ansehen

Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten

01:29 AM

Molecular Diagnostics in Pharmacogenomics Market to Reach USD - openPR.com

01:29 AM

Sep 24, 2025

HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer? - TradingView

Sep 24, 2025

Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East - Quantisnow

Sep 16, 2025

Sep 15, 2025

North America In Vitro Diagnostics (IVD) Market Insights and Future Outlook - openPR.com

Sep 15, 2025

Sep 13, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Sep 13, 2025

Sep 09, 2025

Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail

Sep 09, 2025

Sep 08, 2025

iMDx launches 5,000-patient registry to study transplant rejection test - Investing.com

Sep 08, 2025

iMDx launches 5,000-patient registry to study transplant rejection test By Investing.com - Investing.com Nigeria

Sep 08, 2025

Insight Molecular Diagnostics (IMDX) Launches New Patient Regist - GuruFocus

Sep 08, 2025

IMDX Advances GraftAssureDx Clinical Trial for Transplant Rejection Test - GuruFocus

Sep 08, 2025

Insight Molecular Diagnostics Inc. Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants - MarketScreener

Sep 08, 2025

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants - GlobeNewswire

Sep 08, 2025

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database - The Manila Times

Sep 08, 2025

Sep 05, 2025

Insight Molecular Diagnostics Inc. shares rise 1.62% premarket after Myriad Genetics announces positive MRD test results. - AInvest

Sep 05, 2025

Molecular Diagnostics Market: Applications, Growth, and Future Trends - newstrail.com

Sep 05, 2025

Sep 02, 2025

Insight Molecular Diagnostics Inc. shares rise 1.78% intraday after QIAGEN gains U.S. clearance for higher-throughput syndromic testing system. - AInvest

Sep 02, 2025

Aug 26, 2025

iMDx to Participate in NYC Investment Conferences September 811 - GlobeNewswire

Aug 26, 2025

iMDx Announces Participation in NYC Investment Conferences - AInvest

Aug 26, 2025

Molecular Diagnostics Leader iMDx Announces Double-Header NYC Investor Conference Schedule for September - Stock Titan

Aug 26, 2025

Aug 25, 2025

iMDx CFO Andrea James discusses democratizing molecular diagnostics in podcast episode. - AInvest

Aug 25, 2025

IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics - MarketScreener

Aug 25, 2025

Aug 23, 2025

HIV Diagnostics Market Size, Share & Forecast, 2025–2034 - Global Market Insights Inc.

Aug 23, 2025

Aug 20, 2025

Global Minimal Residual Disease Testing Market Gearing Up for Outstanding Expansion at a CAGR of ~11% by 2032 | DelveInsight - PR Newswire UK

Aug 20, 2025

Aug 19, 2025

Insight Molecular Diagnostics: Pioneering the Next Generation of Transplant Rejection Testing and FDA Readiness - AInvest

Aug 19, 2025

Veterinary Molecular Diagnostics Market on Track for Massive Expansion by 2035, Forecasts Reveal. - newstrail.com

Aug 19, 2025

Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Insight Molecular Diagnostics (IMDX) - The Globe and Mail

Aug 19, 2025

Sepsis Diagnostics Market Poised for Remarkable Expansion by 2035, Reveals Prophecy Market Insights Study - newstrail.com

Aug 19, 2025

Aug 18, 2025

Insight Molecular Diagnostics Inc. shares rise 12.92% intraday after Myriad Genetics appoints new CFO. - AInvest

Aug 18, 2025

Molecular Diagnostics Market Evolving Rapidly from 2025 to 2032 | F. Hoffmann-La Roche Ltd, Illumina, Inc. - openPR.com

Aug 18, 2025

Insight Molecular: Needham Reiterates Buy Rating with $4.25 PT - AInvest

Aug 18, 2025

Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛

Aug 18, 2025

Aug 15, 2025

Insight Molecular Diagnostics: Paving the Next Frontier in Transplant Rejection Testing with FDA-Ready Innovation - AInvest

Aug 15, 2025

IMDX’s GraftAssureDx Study: A Game-Changer in Kidney Transplant Monitoring? - TipRanks

Aug 15, 2025

Insight Molecular Diagnostics Inc. shares rise 1.21% intraday after Caris Life Sciences validates MI Cancer Seek® assay. - AInvest

Aug 15, 2025

Aug 14, 2025

Insight Molecular Diagnostics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

Aug 14, 2025

Aug 13, 2025

Insight Molecular Diagnostics : With Q&A (insight molecular diagnostics inc imdx us q2 2025 earnings call 11 august 2025 5 00 pm et) - MarketScreener

Aug 13, 2025

Lake Street Sticks to Their Buy Rating for Insight Molecular Diagnostics (IMDX) - The Globe and Mail

Aug 13, 2025

In Vitro Diagnostics Market to Hit USD 197.06 Billion by 2032, Driven by a Surge in Chronic and Infectious Disease Burden | Coherent Market Insights - BioSpace

Aug 13, 2025

Aug 12, 2025

Insight Molecular Diagnostics Inc. shares fall 1.53% intraday after reporting a Q2 loss of $9.7 million. - AInvest

Aug 12, 2025